All
Glioblastoma Vaccine to Be Tested as Orphan Drug, Easing Clinical Trials Process
August 19th 2017The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.
Maintenance Lynparza Tablets Approved in Ovarian Cancer
August 17th 2017Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
The Surprising Link Between Cancer Caregiver Burden and Patient Self Image
August 17th 2017This disconnect can lead to increased burden for caregivers. Researchers from City of Hope National Medical Center in Duarte, California, found that patients view themselves as being more able than their caregivers thought.
A Promising New Agent for Epithelial Ovarian Cancer
August 15th 2017A new agent showed a favorable toxicity profile for patients with epithelial ovarian cancer. The drug, mirvetuximab soravtansine (IMGN853), also demonstrated encouraging clinical activity in a phase 1 trial presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.